PCT Patent Entry into China: A Cost Lock-In Mechanism Many Applicants Overlook
There is a moment, usually around month 28 or 29 of your PCT application’s life, when your China IP strategy becomes a cost reality. The application that started as an idea — and grew through drafting, international search, and maybe some Article 19 amendments — now has to become a paid-up Chinese patent prosecution.
What many applicants find surprising is how much of that cost was already locked in by decisions made much earlier. This is what I call the cost lock-in mechanism of PCT entry into China.
What Gets Locked In at National Phase Entry
When you enter China’s national phase, CNIPA’s official fees are calculated based on the application as it stands at entry. Specifically:
1. Claim count. Send the international application and its claim count so the filing agent can check which official fees apply.
2. Page count for specification. China’s official fee structure also includes charges based on application length above a base threshold. A long international specification — common in US and European biotech or software filings — translates to elevated fees.
3. Translation volume. Unlike most Western patent offices, CNIPA requires a complete Chinese translation of your entire application at national phase entry. The word count in your international specification drives translation costs directly. A 200-page biotech specification translated at professional patent rates is a significant line item.
4. Claim structure. Applications with several independent claims can require additional review. The agent can explain what work is included in the quote.
Why “Lock-In” Happens in Practice
These cost drivers are not surprising in isolation. What makes them a lock-in mechanism is that they were all set at the time your international PCT application was drafted — often 18 to 28 months before you ever think about China costs.
The original PCT drafter may have been a US firm optimizing for a large US claim set. The specification may be 150 pages because that’s what a US biotech application requires. The claims may number 30 because that’s what a US prosecution strategy demands.
None of that is wrong for the US. But entering China’s national phase with that original application, unchanged, means you’re paying for a US-optimized filing in a system with a very different fee structure.
The Three Levers You Can Still Pull
Even though costs are largely locked in by the original application, you do have options to reduce them — if you act before national phase entry.
Lever 1: Review the claim set. A China patent agent can review commercially important claims, any proposed amendments and how the applicable official fees are calculated.
Lever 2: Confirm the translation scope. Identify the original application and any international amendments. Ask the agent which texts must be translated for entry before setting the budget.
Lever 3: Time your filing carefully. CNIPA applies fee rates based on the filing date. Fee schedules are periodically updated. While this is not always a controllable variable, large multinationals with portfolios sometimes time batch filings to a known fee period.
Requesting a China Entry Quote
The agency fee for PCT national phase entry in China starts at USD 500. Official fees and translation fees are quoted separately.
For a China entry quote, send your PCT application number, language, page count, claim count and deadline.
The Upstream Solution
The best time to manage China national phase costs is not at month 29. It’s at the drafting stage, when you structure your PCT application with China’s fee logic in mind.
This doesn’t mean writing a weaker patent. It means structuring claims and specifications in a way that is both strong for the US and efficient for China — not identical, but compatible.
Ready to plan your China national phase entry?
Our China Patent team works with applicants at every stage of the PCT timeline. Or speak with a China Patent Attorney to review your pending applications before the 30-month deadline.